Drug General Information (ID: DDIUL5EQPF)
  Drug Name Guanabenz Drug Info Trichlormethiazide Drug Info
  Drug Type Small molecule Small molecule
  Therapeutic Class Sympatholytics Antihypertensive Agents
  Structure

 Mechanism of Guanabenz-Trichlormethiazide Interaction (Severity Level: Moderate)
     Additive hypotensive effects Click to Show/Hide Mechanism Graph
Could Not Find 2D Structure
      Drug Name Guanabenz Trichlormethiazide
      Mechanism Antihypertensive agent
Alpha-2 adrenergic receptor  Agonist
Antihypertensive agent
      Key Mechanism Factor 1
Factor Name Adrenergic receptor alpha-2 Structure Sequence
Protein Family G-protein coupled receptor 1 family
Protein Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazoline > clonidine > epinephrine > norepinephrine > phenylephrine > dopamine > p-synephrine > p-tyramine > serotonin = p-octopamine. For antagonists, the rank order is yohimbine > phentolamine = mianserine > chlorpromazine = spiperone = prazosin > propanolol > alprenolol = pindolol.
    Click to Show/Hide
      Mechanism Description
  • Additive hypotensive effects by the combination of Guanabenz and Trichlormethiazide 

Recommended Action
      Management Hemodynamic responses should be monitored during coadministration, especially during the first few weeks of therapy. Patients should be advised to take the alpha-blocker at bedtime and to notify their physician if they experience dizziness or syncope while awake.

References
1 Cohen J "Long-term efficacy and safety of terazosin alone and in combination with other antihypertensive agents." Am Heart J 122 (1991): 919-25. [PMID: 1678923]
2 Pool JL "Combination antihypertensive therapy with terazosin and other antihypertensive agents: results of clinical trials." Am Heart J 122 (1991): 926-31. [PMID: 1678924]
3 Product Information. Xatral (alfuzosin). Sanofi-Synthelabo Canada Inc, Markham, ON.